DAUVILLIERS Yves, MD, PhD
Born Jan 29th 1970, Paris, France, married, two children
Professional address : Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, 80 Avenue Augustin Fliche, 34295 Montpellier cedex 5, France
Tel: +33 4 67 33 72 77 Fax: +33 4 67 33 72 85
E-mail:
[email protected] [email protected]
N° Conseil de l’ordre des Médecins : 34/10354 / N° RPPS : 10003245817
Scholarship
Specialist in Neurology, Montpellier University, 1995
Medical thesis, “Genetic and familial aspects of narcolepsy”, Montpellier, 2000
PhD in Neurosciences “Neurobiology and Genetics of Narcolepsy”, Montpellier, 2004
Professor of Neurology-Physiology, 2007
Professional experience
Director of the Sleep Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier
Coordinator of the National Reference Network for Orphan Diseases: Narcolepsy and Rare Hypersomnias
Coordinator of Team:Sleep pathologies, INSERM U1061 Neuropsychiatry: Clinical and Epidemiological Research
Member of the Clinical Research Department, University Hospital, Montpellier
Coordinator of Fédération Hospitalo-Universitaire Neuroscience « NEUROCLIN»
Member of governance of Brainteam (Filière nationale de Soins) and of the COEN of Montpellier
Member of the Scientific board of the Medical University of Montpellier
Member of Societies and board
Member of governance of Brainteam (Filière nationale de Soins) and of the COEN of Montpellier
Coordinator of Team : Neuropeps (Sleep), INSERM Institut of neuroscience
Coordinator of the National Reference Network for Orphan Diseases: Narcolepsy and Idiopathic Hypersomnia
President of the European Narcolepsy Network
President of French Sleep Medical and Research Society (SFRMS)
Past Vice-President of EU Restless Legs Syndrome
Member of the Editorial Board for Sleep Medecine and SLEEP.
Main domain of research
Sleep and Neurology
Narcolepsy and other central hypersomnias
Parasomnia and restless legs syndrome
Major grants
1 ERA-Net (Narcomics 2018), 4 ANR (Narcogene, ImmunitySleep, NarConX, NarcoT1), 4 PHRC, 1 FIU, several grants from fondations or private companies (FRC, Apard, AFE, UCB, JAZZ…)
Expert
Involvement in many clinical trials in sleep disorders: > 20 RCT
Participation in European Commission: European Brain council and E-rare
Grant evaluation: PHRC and ANR reviewing
Institutional committees: Experts for Afssaps and ONIAM (H1N1 vaccination issues)
Participation to national (for patients, general public, researchers, clinicians and students) and international (EU) training programs each year (EUNN and Narcolepsy MasterClass) on narcolepsy, RLS
Co-organization of the 7th International Narcolepsy Symposium, Boston-US, September 2018
Key interaction with Patient’s Association in France (ANC:president scientific committee, KLS, RLS)/ UK
Large public outreach: Radio-TV (Europe1, France-inter, TF1, France2-3), Journal articles (Figaro, Le Monde, Recherche)
Oral communication
Invited conferences in international congress US-Canada (3-4 per year, Harvard-Stanford), in EU (4 per year)
Consulting
Consulting for big pharma (UCB, Jazz, Idorsia, Takeda, Bioprojet) and start-ups (Theranexus)
1 patent (EU patent “Method for in vitro diagnosis of a neurological disorder”: 1000192566 )
Quantified production
H-index: 84, Author or coauthor of more than 590 papers published in international and national peer-reviewed journals (including Lancet, Lancet Neurol, Science, Nature Genetic), several book chapters, and also editor of three French book related to sleep medicine.
10 relevant publications
1. Dauvilliers Y, Plazzi G, Mignot E, et al. Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1.N Engl J Med. 2025 ;392:1905-1916.
2. Dauvilliers Y, Mignot E, Del Río Villegas R, et al. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1. N Engl J Med. 2023 Jul 27;389(4):309-321
3. Pérez-Carbonell L, Mignot E, Leschziner G, Dauvilliers Y. Understanding and approaching excessive daytime sleepiness. Lancet. 2022 24;400(10357):1033-1046.
4. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369:499-511
5. Maret S, Franken P, Dauvilliers Y, Ghyselinck NB, Chambon P, Tafti M. Retinoic acid signaling affects cortical synchrony during sleep. Science. 2005; 7:111-3
6. Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, et al. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022 Jan;21(1):53-65
7. Dauvilliers Y, Bassetti C, Lammers GJ et al. HARMONY I study group. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12:1068-75.
8. Dauvilliers Y, Lecendreux M, Lammers GJ, et al. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placeb
